VA-NEUSTAR-INC.
13.10.2021 09:02:08 CEST | Business Wire | Press release
Neustar Inc., a global information services and technology company and leader in identity resolution, today announces the redesign of the company’s Partner Program, renamed ‘Ultra Secure Partner Program’ (USPP). Providing enhanced channel access to its unmatched range of cloud-based security solutions, globally distributed network, and mature family of security services, partners can now easily curate and grow their cloud security portfolios.
In addition, Neustar Security Solutions also announces the appointment of Jeremy Nicholls as Vice President of Global Channels. The move comes as part of a wider effort to further grow the company’s channel business.
Ahead of joining Neustar in January 2021, Jeremy was Vice President of Global Channels & Alliances at Arbor Networks for 9 years. He has also held channel and direct sales leadership roles at Niksun, Polycom, and Ericsson and holds an MBA from Bath University in the UK.
Ultra Secure Partner Program
The newly designed program provides a clearly defined tiered structure for its partners to operate within, ensuring clarity on expectations from both parties, with consistent practices, policies, and discounts. Now a standardized, tiered program, the USPP offers varying benefits and expectations to partners depending upon the commitment made, with benefits increasing in higher tiers.
Higher levels of partnership have benefits including, but not limited to: higher discounting, qualified sales leads, training and support, account mapping, access to Neustar specialists and expertise, and focused marketing support, such as promotional materials, customizable collateral, special program funding, and case studies, to help partners generate more business. Discounts offered throughout the program have been increased to afford leading margins to partners, with rates varying by partner tier and reflective of partner engagement levels.
“We’ve reimagined Neustar Security Solutions’ partner program to make it as compelling as possible. Now a simple and value-driven program based on partner engagement levels, we offer highly competitive margins and unrivalled support to our partners ,” said Jeremy Nicholls. “As the world continues to move to the cloud, Neustar Security Solutions is uniquely positioned to partner with organisations who want to grow existing, and secure new customers based around cloud security, where they can wrap their own incremental services to the offerings. ”
Ed Lorenzini, CEO, Analyze Corporation said: “Neustar Security Solutions is a trusted partner of Analyze Corporation. This revamped and standardised program makes growing our business easier and even more rewarding. By participating in Neustar’s USPP, we are able to provide our customers with world-leading security solutions, support and insights that map to their cloud needs.”
Güngör Gündoğdu, Managing Director, Inforte added: “In this growing landscape, we at Inforte have found a valued partner in Neustar Security Solutions. By participating in Neustar’s USPP, our work together is smooth and straightforward, from customer registration through to delivery.”
The new channel partner programs are specifically targeted to expand sales and support coverage for Neustar Security Solutions in the United States, Canada, and Europe, with additional opportunities in Latin America and Eastern Europe.
For more information about the program, visit https://www.home.neustar/about-us/partners/security-partners or contact partners@team.neustar for a direct engagement.
About Neustar
Neustar is an information services and technology company and a leader in identity resolution providing the data and technology that enables trusted connections between companies and people at the moments that matter most. Neustar offers industry-leading solutions in Marketing, Risk, Communications, and Security that responsibly connect data on people, devices and locations, continuously corroborated through billions of transactions. Neustar serves more than 8,000 clients worldwide, including 60 of the Fortune 100. Learn how your company can benefit from the power of trusted connections here: https://www.home.neustar
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20211013005047/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom